Skip to Main Content

Paper Details

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.
J Clin Oncol
2
2023
Author NameAffiliation
Vinay K JainUniversity of Texas M.D. Anderson Cancer Center
  • 1 - 1

Datasets

Release 1.2